FBRX — Forte Biosciences, Inc.

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 14
• Website: https://www.fortebiorx.com

Latest SEC filings for FBRX

• 15-12G — 2026-09-08
• 15-12G — 2026-09-08
• 15-12G — 2026-09-08
• SCHEDULE 13G/A — 2026-09-08
• EFFECT — 2026-09-02
• EFFECT — 2026-09-02
• EFFECT — 2026-09-02
• EFFECT — 2026-09-02
• EFFECT — 2026-09-02
• 25-NSE — 2026-08-27

Abrir análisis completo

Educational tool only — not investment advice.